Literature DB >> 10848650

Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.

K G Mandel1, B P Daggy, D A Brodie, H I Jacoby.   

Abstract

Alginate-based raft-forming formulations have been marketed word-wide for over 30 years under various brand names, including Gaviscon. They are used for the symptomatic treatment of heartburn and oesophagitis, and appear to act by a unique mechanism which differs from that of traditional antacids. In the presence of gastric acid, alginates precipitate, forming a gel. Alginate-based raft-forming formulations usually contain sodium or potassium bicarbonate; in the presence of gastric acid, the bicarbonate is converted to carbon dioxide which becomes entrapped within the gel precipitate, converting it into a foam which floats on the surface of the gastric contents, much like a raft on water. Both in vitro and in vivo studies have demonstrated that alginate-based rafts can entrap carbon dioxide, as well as antacid components contained in some formulations, thus providing a relatively pH-neutral barrier. Several studies have demonstrated that the alginate raft can preferentially move into the oesophagus in place, or ahead, of acidic gastric contents during episodes of gastro-oesophageal reflux; some studies further suggest that the raft can act as a physical barrier to reduce reflux episodes. Although some alginate-based formulations also contain antacid components which can provide significant acid neutralization capacity, the efficacy of these formulations to reduce heartburn symptoms does not appear to be totally dependent on the neutralization of bulk gastric contents. The strength of the alginate raft is dependant on several factors, including the amount of carbon dioxide generated and entrapped in the raft, the molecular properties of the alginate, and the presence of aluminium or calcium in the antacid components of the formulation. Raft formation occurs rapidly, often within a few seconds of dosing; hence alginate-containing antacids are comparable to traditional antacids for speed of onset of relief. Since the raft can be retained in the stomach for several hours, alginate-based raft-forming formulations can additionally provide longer-lasting relief than that of traditional antacids. Indeed, clinical studies have shown Gaviscon is superior to placebo, and equal to or significantly better than traditional antacids for relieving heartburn symptoms. Alginate-based, raft-forming formulations have been used to treat reflux symptoms in infants and children, and in the management of heartburn and reflux during pregnancy. While Gaviscon is effective when used alone, it is compatible with, and does not interfere with the activity of antisecretory agents such as cimetidine. Even with the introduction of new antisecretory and promotility agents, alginate-rafting formulations will continue to have a role in the treatment of heartburn and reflux symptoms. Their unique non-systemic mechanism of action provides rapid and long-duration relief of heartburn and acid reflux symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10848650     DOI: 10.1046/j.1365-2036.2000.00759.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  34 in total

1.  A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms.

Authors:  Edoardo G Giannini; Patrizia Zentilin; Pietro Dulbecco; Elena Iiritano; Claudio Bilardi; Edoardo Savarino; Carlo Mansi; Vincenzo Savarino
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

2.  Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease.

Authors:  I-Rue Lai; Ming-Shiang Wu; Jaw-Town Lin
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 3.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.

Authors:  Katsuhiko Iwakiri; Yoshikazu Kinoshita; Yasuki Habu; Tadayuki Oshima; Noriaki Manabe; Yasuhiro Fujiwara; Akihito Nagahara; Osamu Kawamura; Ryuichi Iwakiri; Soji Ozawa; Kiyoshi Ashida; Shuichi Ohara; Hideyuki Kashiwagi; Kyoichi Adachi; Kazuhide Higuchi; Hiroto Miwa; Kazuma Fujimoto; Motoyasu Kusano; Yoshio Hoshihara; Tatsuyuki Kawano; Ken Haruma; Michio Hongo; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

Review 4.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

5.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

Review 6.  Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.

Authors:  Rena Yadlapati; Kelli DeLay
Journal:  Med Clin North Am       Date:  2018-11-01       Impact factor: 5.456

Review 7.  Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.

Authors:  Mark P Tighe; Nadeem A Afzal; Amanda Bevan; R Mark Beattie
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 8.  NERD: an umbrella term including heterogeneous subpopulations.

Authors:  Edoardo Savarino; Patrizia Zentilin; Vincenzo Savarino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

9.  Alginate controls heartburn in patients with erosive and nonerosive reflux disease.

Authors:  Edoardo Savarino; Nicola de Bortoli; Patrizia Zentilin; Irene Martinucci; Luca Bruzzone; Manuele Furnari; Santino Marchi; Vincenzo Savarino
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

Review 10.  Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.

Authors:  Shlomi Cohen; Mirjam Bueno de Mesquita; Francis B Mimouni
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.